Preparation, characterization, in vivo biodistribution and pharmacokinetic studies of donepezil-loaded PLGA nanoparticles for brain targeting

Drug Development and Industrial Pharmacy

Volumn 40, Issue 2, 2014, Pages 278-287

  Bhavna, B ^a   Shadab, M ^a   Ali, Mushir ^a   Baboota, Sanjula ^a   Sahni, Jasjeet Kaur ^a   Bhatnagar, Aseem ^b   Ali, Javed ^a  

^a HAMDARD UNIVERSITY   (India)

^b INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

Alzheimer's disease; Cholinesterase inhibitor; Gamma scintigraphy; Nanoparticles; Solvent emulsification diffusion evaporation

Indexed keywords

DONEPEZIL; POLYGLACTIN; POLYSORBATE 80;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIFFUSION; DRUG BRAIN LEVEL; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG SOLUTION; DRUG SYNTHESIS; DRUG TARGETING; EVAPORATION; GAMMA SCINTIGRAPHY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; NANOEMULSION; NONHUMAN; PARTICLE SIZE; RAT; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION; ZETA POTENTIAL;

ANIMALS; BRAIN; DRUG DELIVERY SYSTEMS; INDANS; LACTIC ACID; NANOPARTICLES; PARTICLE SIZE; PIPERIDINES; POLYGLYCOLIC ACID; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 84893271973     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.758130     Document Type: Article

References (41)

1. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983;219:1184-90.
2. Giacobini E, Becker R. Development of drugs for Alzheimer therapy: a decade of progress. In: Giacobini E, Becker R., eds. Alzheimer disease: therapeutic strategies. Boston (MA): Birkhauser; 1994:1-7.
3. Christodoulou C, Melville P, Scherl WF, et al. Effects of donepezil on memory and cognition in multiple sclerosis. J Neurol Sci 2006;245:127-36.
4. Haque S, Md S, Alam MI, et al. Nanostructure-based drug delivery systems for brain targeting. Drug Dev Ind Pharm 2012;38:387-411.
5. Paolino D, Cosco D, Molinaro R, et al. Supramolecular devices to improve the treatment of brain diseases. Drug Discov Today 2011;16:311-24.
6. Joshi SA, Chavhan SS, Sawant KK. Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur J Pharm Biopharm 2010;76:189-99.
7. Pillay S, Pillay V, Choonara YE, et al. Design, biometric simulation and optimization of a nano-enabled scaffold device for enhanced delivery of dopamine to the brain. Int J Pharm 2009;382:277-99.
8. Cho K, Wang X, Nie S, et al. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008;14:1310-16.
9. Sehra S, Dhake AS. Formulation and evaluation of sustained release 611 microspheres of poly-lactide-co-glycolide containing tamoxifen citrate. J Microencaps 2005;22:521-8.
10. Barichello JM, Morishita M. Takayama K, Nagai T. Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Develop Ind Pharm 1999;25:471-6.
11. Avgoustakis K. Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. Curr Drug Del 2004;1:321-33.
12. Fonseca C, Simoes S, Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Rel 2002;83:273-86.
13. Bala I, Hariharan S, Ravi Kumar MNV. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carriers 2004;21:387-422.
14. Kumar MNVR, Bakowsky U, Lehr CM. Preparation and characterization of cationic PLGA nanospheres as donepezil carriers. Biomaterials 2004;25:1771-7.
15. Peltonen L, Koistinen P, Karjalainen M, et al. The effect of cosolvents on the formulation of nanoparticles from low molecular weight poly(l)lactide. AAPS PharmSciTech 2002;3:1-7.
16. Cui F, Oian F, Yin C. Preparation and characterization of mucoadhesive polymercoated nanoparticles. Int J Pharm 2006; 316:154-61.
17. Dou H, Jiang M. Fabrication, characterization and drug loading of pH-dependent multi-morphological nanoparticles based on cellulose. Polym Int 2007;56:1206-12.
18. Jeong YI, Cheon JB, Kim SH, et al. Clonazepam release from coreshell type nanoparticles in vitro. J Control Release 1998;51:169-78.
19. Md S, Kumar M, Baboota S, et al. Preparation, characterization and evaluation of bromocriptine loaded chitosan nanoparticles for intranasal delivery. Sci Adv Mater 2012;2:1-12.
20. Reddy L, Sharma R, Chuttani K, et al. Etoposide-incorporated tripalmitin nanoparticles with different surface charge: formulation, characterization, radiolabeling, and biodistribution Studies. AAPS J 2004;6:23.
21. Agnihotri SM, Vavia PR. Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application. Nanomedicine 2009;5:90-95.
22. Allemann E, Gurny R, Deolker E. Drug loaded nanoparticles: preparation methods and drug targeting issues. Eur J Pharm Biopharm 1993;39:173-91.
23. Banerjee T, Mitra S, Singh AK, et al. Preparation and biodistribution of ultrafine chitosan nanoparticles. Int J Pharm 2002;243:93-105.
24. Wisse E, Leeuw AM. Structural elements determining transport and exchange process in the liver. In: Daviss SS, Illum L, McVie JG, Tomlinson E., eds. Microspheres and drug therapy, pharmaceutical, immunological and medical aspects. Amsterdam: Elsevier; 1984: 1-23.
25. Hans ML, Lowman AM. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci 2002;6: 319-27.
26. Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001;47: 3-19.
27. Vila A, Sa'nchez A, Tobi'o M, et al. Design of biodegradable particles for protein delivery. J Control Release 2002;78:15-24.
28. Reddy LH, Murthy RSR. Pharmacokinetics and biodistribution studies of doxorubicin loaded poly(butylcyanoacrylate) nanoparticles synthesized by two different techniques. BioMed 2004;148:161-6.
29. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 2001;70:1-20.
30. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001;47:65-81.
31. Kreuter J. Transport of drugs across the blood-brain barrier by nanoparticles. Curr Med Chem CNS Agents 2002;2:241-49.
32. Kreuter J. Influence of the surface properties on nanoparticlemediated transport of drugs to the brain. J Nanosci Nanotechnol 2004;4:484-8.
33. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release 2004;100:5-28.
34. Fawaz F, Guyot M, Lagueny AM, Devissaguet JPH. Ciprofloxacinloaded poly(isobutylcyanoacrylate) nanoparticles: preparation and characterization. Int J Pharm 1997;154:191-203.
35. Wu Y, Yang W, Wang C, et al. Chitosan nanoparticles as a novel delivery system for ammonium glycyrrhizinate. Int J Pharm 2005;295:235-45.
36. Seju U, Kumar A, Sawant KK. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies. Acta Biomater 2011;7:4169-76.
37. Nanda B, Murthy RSR. Preparation and characterization of chitosan lactate nanoparticles for the nasal delivery of enalaprilat. J Biomed Nanotechnol 2007;3:45-51.
38. Budhian A, Siegel SJ, Winey KI. Controlling the in vitro release profiles for a system of haloperidol-loaded PLGA nanoparticles. Int J Pharm 2008;346:151-9.
39. Tayade PT, Kale RD. Encapsulation of water-insoluble drug by a cross-linking technique: effect of process and formulation variables on encapsulation efficiency, particle size, and in vitro dissolution rate. AAPS Pharm Sci 2004;6:1-8.
40. Papadimitriou S, Papageorgiou GZ, Kanaze FI, et al. Nanoencapsulation of nimodipine in novel biocompatible poly (propylene-co-butylene succinate) aliphatic copolyesters for sustained release. J Nanomater 2009;2009:1-11.
41. Mistry A, Stolnik S, Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int J Pharm 2009;379:146-57.